English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

++ ALL) expression of either p210 or p185 can be found. In contrast to its proto-oncogenic counterpart c-ABL, BCR-ABL displays constitutive tyrosine kinase activity. 1 The ATP-competitive BCR-ABL tyrosine kinase inhibitor ima tinib leads to durable remissions in the majority of patients with chronic myelogenous leukemia in the chronic phase and converted chronic myelogenous leukemia to a chronic disease. Imatinib also improved the previously devastating outcome in Ph + ALL patients. However, the occurrence of imatinib resistance mutations in the ABL kinase domain became clinically problematic and led to the development of nilotinib and dasatinib, both also ATP-competitive inhibitors, which target most imatinib-resistant BCR-ABL mutations. 2

haematologica

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance